Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PepGen
Biotech
PepGen hit with partial hold, analyst blames 'understaffed FDA'
The FDA put a partial hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop-start advance of the asset.
Nick Paul Taylor
Mar 5, 2026 5:45am
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
PepGen pauses UK arm of DMD trial that's already on hold in US
Mar 4, 2025 10:25am
FDA hits pause on another of PepGen's muscular dystrophy trials
Dec 16, 2024 9:45am
BioMarin builds exec team with biotech vets—Chutes & Ladders
Aug 23, 2024 8:30am
J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders
Jun 14, 2024 8:30am
